enGene Reports Full Year 2024 Financial Results and Provides a Business Update [Yahoo! Finance]
enGene Holdings Inc. (ENGN)
Company Research
Source: Yahoo! Finance
All cohorts of the Phase 2 LEGEND study now recruiting under updated protocol Additional preliminary data from pivotal cohort anticipated in 2H 2025 Cash, cash equivalents and marketable securities of $297.9 million provide runway into 2027 BOSTON & MONTREAL, December 19, 2024 BUSINESS WIRE )--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), announced its financial results for the full year ended October 31, 2024 and provided a business update. "Having demonstrated a 71% anytime complete response rate in the preliminary data from the LEGEND study's pivotal cohort of BCG-unresponsive NMIBC patients, initiated three additio
Show less
Read more
Impact Snapshot
Event Time:
ENGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENGN alerts
High impacting enGene Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ENGN
News
- enGene Holdings Inc. (NASDAQ: ENGN) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $18.00 price target on the stock.MarketBeat
- enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $25.00 price target on the stock.MarketBeat
- enGene Holdings Inc. (ENGN) Upgraded to Strong Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- enGene Reports Full Year 2024 Financial Results and Provides a Business UpdateBusiness Wire
- enGene Holdings Inc. (NASDAQ: ENGN) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $18.00 price target on the stock.MarketBeat
ENGN
Sec Filings
- 12/20/24 - Form 8-K
- 12/20/24 - Form 424B5
- 12/19/24 - Form 10-K
- ENGN's page on the SEC website